Skip main navigation

Response to Letter From Watanabe and Aizawa Regarding Article, “Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study,” by Lopez et al

Originally publishedhttps://doi.org/10.1161/CIRCEP.112.971960Circulation: Arrhythmia and Electrophysiology. 2012;5:e81

    We thank Drs Watanabe and Aizawa1 for their letter concerning our recent publication in Circulation Arrhythmia and Electrophysiology, “Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation.” In their letter, they ask whether the association of lipids with the risk of atrial fibrillation observed in the Atherosclerosis Risk in Communities cohort was modified by age or sex.

    In our published analysis, we did not detect any significant interactions by age categories (using mean age to create a dichotomous variable) or sex for any of the lipid levels. These issues are noted in the results and discussion sections of the article. As suggested by Drs Watanabe and Aizawa, we reanalyzed the data by using an age cutoff of 50 years and further stratifying by sex. After multivariable adjustment, we did not find any significant interactions between age, sex, and low-density lipoprotein or high-density lipoprotein cholesterol.

    We agree with the authors that the paradox found between higher levels of total cholesterol and low-density lipoprotein cholesterol with a lower incidence of atrial fibrillation is intriguing and complex. Additional research using cohort data should evaluate this question further, and, if the results are replicated, future focus should be to study the underlying mechanisms.

    Faye L. Lopez, MS, MPHRachel R. Huxley, DPhilSuma Konety, MD, MSAlvaro Alonso, MD, PhDDivision of Epidemiology and Community HealthSchool of Public HealthUniversity of MinnesotaMinneapolis, MNSunil K. Agarwal, MD, PhDDepartment of EpidemiologyGillings School of Global Public HealthUniversity of North CarolinaChapel Hill, NCRichard F. MacLehose, PhDDivision of Epidemiology and Community HealthDivision of BiostatisticsSchool of Public HealthUniversity of MinnesotaMinneapolis, MNElsayed Z. Soliman, MD, MSc, MSDepartment of EpidemiologyDivision of Public Health SciencesWake Forest University School of MedicineWinston-Salem, NCA. Richey Sharrett, MD, DrPHDepartment of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimore, MDChristie M. Ballantyne, MDBaylor College of MedicineHouston, TXMethodist DeBakey Heart and Vascular CenterHouston, TX

    Disclosures

    None.

    Reference

    • 1. Lopez FL, Agarwal SK, Maclehose RF, Soliman EZ, Sharrett AR, Huxley RR, Konety S, Ballantyne CM, Alonso A.Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities 5 (ARIC) Study.Circ Arrhythm Electrophysiol.2012; 5:155–162.LinkGoogle Scholar

    eLetters(0)

    eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

    Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.